esmoThe European society of medical oncology has its annual meeting in Madrid in exactly four months.
At that time, it is reasonable to expect that the investigators will provide:
- updates on the PADC results that were presented as response rates last October. By next fall they may have OS as well as PFS.
- the first real results on CRC. Based on recent articles published in the Nature journals, CRC may well become our third ph 2 ready indication.
- the initital results on first line and third line analy cancer.
There are high hopes, based on sound science for the role of pela in these kinds of solid tumors combined with Tecentriq, owned by Roche.
From where I sit, Roche seems like the right candidate for a buy-out.